Olema Pharmaceuticals, Inc. (OLMA)
Develops cancer drugs targeting breast cancer and other solid tumors in clinical trials.
$11.62-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+118.0%
The outlook
OLMA trades near $11.62, well below both its 50- and 200-day moving averages and sitting near the lower end of its 52-week range. Analyst coverage shows an average price target around 250% above the current price, though the overall sentiment leans bearish. The stock's technical position and sentiment score suggest caution despite the optimistic long-term price targets.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range22% of the way from its 52-week low to high
Price targetAvg target +250% vs current price
Analyst price target
~12-month · 10 analysts$40.70average target+250.3% vs now
Now $11.62
Low $23.00High $62.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.01B
52-wk high
$36.26
52-wk low
$4.47
50-day avg
$11.68
200-day avg
$17.44
Trailing P/E
—